This program combines the frequencies of peptides and a new form of frequencies called the Resonant Recognition Model. Virus Detox 2 targets viruses acquired through infection, shedding, and vaccination.
Hepatitis A, B, C, D, and E
Rhinoviruses A, B, and C (common cold)
Variola Virus (Smallpox)
Human Immunodeficiency Virus (HIV) 1 & 2
Polio Virus
Rabies Virus
The human body is overloaded with toxins, many of which were acquired through vaccination, shedding, or infection. Many viruses are called co-infections and are latent in the body, draining energy and affecting the immune system. When these overloads are addressed, the body can begin to operate at its optimum level and return to a positive state of health and homeostasis. It is generally recommended, after Virus detoxing, to address Bacteria Detox programs.
NOTE: Before Virus Detox 2, it is recommended to address the Epstein-Barr virus (EBV) by going through the Virus Detox 1 program, as 90% of the population is infected and EBV has a significant drain on the immune system. Before any Virus Detox programs, it is recommended to do the Peptide Detox and the Deep Detox as preparation.
If you have a serious concern regarding bacterial infections, it is recommended to do the Virus Detox 1, followed by the necessary Bacteria Detox program/s. Then return to address Virus Detox 2 and 3.
Virus Detox 2
Antiviral (General)
Peptides address general antiviral activity, including membrane disruption, inhibition of viral entry and fusion, immune system balance and support, and antimicrobial effects, offering antiviral properties.
Common Cold
The common cold is an acute viral infection of the upper respiratory tract, primarily caused by rhinoviruses and other viruses, resulting in symptoms such as a runny nose, congestion, sore throat, cough, and mild fever, typically self-limiting but can lead to complications in vulnerable populations.
Peptides address viral membrane disruption or protease inhibition, enhancing T-cell responses and interferon production, anti-inflammatory effects, cytokine suppression, and symptomatic relief through mucosal healing.
Hepatitis A
Hepatitis A is an acute viral liver infection caused by the hepatitis A virus (HAV), a non-enveloped RNA picornavirus transmitted primarily via the fecal-oral route through contaminated food, water, or close personal contact. It predominantly affects the liver, leading to inflammation without progressing to chronic disease in the vast majority of cases, with full recovery typically within weeks to months. Symptoms often include fatigue, nausea, vomiting, abdominal pain, loss of appetite, low-grade fever, dark urine, jaundice, and pale stools, though many infections—especially in children—are asymptomatic.
Peptides address stabilization and protection of liver tissue during acute viral assault, reduction of excessive inflammation and immune-mediated damage, and promotion of regenerative healing with antioxidant support to facilitate resolution.
Hepatitis B
Hepatitis B is a viral liver infection caused by HBV that can cause acute or chronic disease, leading to inflammation, fibrosis, cirrhosis, and increased cancer risk.
Peptides address HBV inhibition, protein expression and replication, antimicrobial action, oxidative stress, liver inflammation and healing, fibrosis, antioxidant protection, and regeneration.
Hepatitis C
Peptides address antiviral inhibition and viral replication, immunomodulation to enhance immune clearance, anti-inflammation to reduce liver inflammation, antimicrobial activity, hepatoprotection to protect liver cells, and regeneration to promote liver tissue repair.
Hepatitis D
Hepatitis D, also known as Hepatitis Delta, is a severe liver infection caused by the hepatitis D virus (HDV), a unique defective satellite RNA virus that requires concomitant infection with the hepatitis B virus (HBV) to replicate and assemble virions, as HDV utilizes the HBV envelope proteins (HBsAg) for entry, assembly, and transmission. Transmission occurs via percutaneous exposure to infected blood or body fluids, sexual contact, or perinatally, predominantly affecting individuals with chronic HBV. Acute co-infection with HBV and HDV can cause fulminant hepatitis, while superinfection in chronic HBV carriers leads to chronic HDV in over 90% of cases, markedly accelerating liver fibrosis, cirrhosis (in 10-20 years), decompensated liver disease, and hepatocellular carcinoma, with mortality rates significantly higher than HBV mono-infection.
Symptoms include fatigue, jaundice, abdominal pain, nausea, dark urine, and, in advanced stages, ascites, encephalopathy, and bleeding varices. Pathophysiology involves HDV binding to the NTCP receptor for hepatocyte entry (mediated by preS1 domain interaction), nuclear import, rolling-circle replication of genomic RNA using host RNA polymerase II, self-cleavage via intrinsic ribozyme activity, production of hepatitis delta antigens (small HDAg for replication, large HDAg —prenylated—for assembly inhibition and virion formation with HBsAg), and host immune-mediated damage exacerbated by inflammatory cytokines and cytotoxic T cells.
Peptides address Hepatitis D inhibition, reduction of viral entry and viral load, disruption of pathway interactions and assembly, interferon mimicry for antiviral protection, anti-inflammatory and immunomodulatory actions, mitigation of liver damage, and anti-fibrotic effects to slow progression.
Hepatitis E
Hepatitis E liver infections are caused by a single-stranded RNA virus primarily transmitted through the fecal-oral route via contaminated water or food, with zoonotic sources like undercooked pork common in some regions. It is the leading cause of acute viral hepatitis globally, with an estimated 20 million infections annually, mostly in developing areas but increasing in developed countries via zoonosis. The disease is typically acute and self-limiting in healthy individuals (incubation 2-6 weeks, symptoms including jaundice, fatigue, nausea, vomiting, abdominal pain, fever, dark urine), resolving in 4-6 weeks, but carries high mortality (20-30%) in pregnant women, especially in the third trimester, due to fulminant hepatic failure. Chronic infection occurs in immunocompromised patients (e.g., transplant recipients, HIV), leading to rapid fibrosis and cirrhosis.
Peptides address viral release inhibition, reducing extracellular virus levels, blocking entry or disrupting assembly, enhancing innate immunity, reducing inflammation and oxidative stress, supporting hepatocyte protection, chronic management, and reducing the severity of infection.
Smallpox
Smallpox is an infectious disease caused by the variola virus, which historically caused high mortality through fever, pustular rash, and systemic complications.
Peptides address antiviral and antimicrobial protection, inhibition of vaccinia virus replication, mitigation of inflammatory response, countering excessive inflammation and cytokine release in poxvirus infections, blocking of intracellular mature virion binding and entry, neutralization of extracellular enveloped virion (EEV) forms, disruption of EEV dissemination, and promotion of protective immunity.
HIV/AIDS
Peptides address therapeutic axes for HIV/AIDS: fusion inhibition to prevent viral entry, antiviral activity to inhibit HIV replication, immunomodulation to enhance immune response, and broad-spectrum antimicrobial coverage. Designed peptides offer neuroprotective and additional anti-inflammatory mechanisms.
Poliomyelitis (Polio)
Poliomyelitis is a highly infectious viral disease caused by poliovirus, which can invade the central nervous system and cause irreversible paralysis in severe cases.
Peptides inhibit viral entry, block viral attachment, prevent viral replication, and provide broad antiviral protection.
Rabies
Rabies is an acute, nearly always fatal viral zoonosis caused by the rabies virus, leading to progressive encephalitis.
Peptides address the inhibition of entry, replication, and attachment; immune system balance and enhancement, neuron protection, inflammation reduction and anti-inflammatory properties, virion disruption, intracellular antiviral protection, T-cell function, neuroprotection and neurorecovery, mitochondrial protection, gastric tissue healing, and rabies virus inactivation
Resonant Recognition Model (RRM)
RRM frequencies offer a new way to address how proteins and other molecules in living things interact. Think of it like this: proteins are long chains of building blocks, and each chain has a hidden pattern that acts like a specific radio frequency. Just as radios tune into the same station to play the same song, proteins with matching frequencies can “hear” each other and work together, even from a distance.
In this model, the protein’s chain is converted into a series of special numbers, based on how electrons move in each building block. These numbers form a signal, similar to a sound wave. By analyzing that signal, we can identify the main frequency, which is like the dominant note in a chord. Proteins that share the same dominant note are more likely to connect for tasks like fighting infections or sending signals in the body.
Here, the frequency comes from the molecule’s overall makeup, much like how different materials in a bell produce different rings. This helps predict if a substance will interfere with a protein’s frequency, blocking negative effects, such as in viruses. RRM is a tool to design better results by matching or disrupting energy patterns. RRM frequencies address:
Hepatitis A (HAV affects 90% of U.S. children in highly endemic regions, with more than 90% of the population being endemic. HAV’s infection rate is much higher worldwide, but only 1.5 million cases are reported annually)
Hepatitis B (estimates indicate that about one-third of the world’s population has been infected with HBV, and around 5% of this population remains HBV carriers. About 25% of these carriers develop chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma)
Hepatitis C (the most prevalent cause of parenteral hepatitis worldwide, and it is prevalent in 0.5% to 2% of the population around the world, with IV drug users and hemophiliacs being the most commonly affected)
Hepatitis D (estimated to affect 4% to 8% of cases of acute HBV and 5% of global chronic HBV patients)
Hepatitis E (HEV is associated with worldwide outbreaks of food and waterborne diseases)
Rhinoviruses A, B, and C (A & B common cold upper respiratory infections, C associated with asthma exacerbations in children)
Variola Virus (Smallpox)
Human Immunodeficiency Virus (HIV) 1 & 2 (1 is the primary cause of AIDS, 2 is a slower progressive form of AIDS)
Polio Virus
Rabies Virus
Emotional Balance
Peptides effectively manage stress, anxiety, and emotional responses, thereby promoting overall mental well-being. Emotional disruptions and imbalances can lead to conditions such as anxiety disorders, depression, or chronic stress. Peptides facilitate emotional balance by modulating neurotransmitter release (serotonin, dopamine, GABA), hormonal regulation (Hypothalamic-Pituitary-Adrenal axis via cortisol), neuropeptide signaling for social interaction, anxiety reduction, stress resilience, neuroprotection, anti-inflammatory effects, mood and pain-related emotions, and sleep regulation.
NOTE: Peptide programs were developed over eight years of research to support molecular-level frequency work. Peptide frequencies offer multitudes of benefits for the body. A particular peptide may be in a certain program for its medically researched and acknowledged benefits for a particular challenge; it may also help in many other areas of the body. If your body doesn’t require the benefit of a particular peptide in frequency form, that peptide will not do anything for you and will not affect you in any negative way.